Purpose: To describe how often patients with depression initiating antidepressants receive their depression diagnosis and prescriptions from the same provider and, when simultaneously initiating benzodiazepines, how often both prescriptions come from the same provider.
| INTRODUCTION
In pharmacoepidemiologic research, appropriate database selection is important, 1 provider-level detail on patient diagnoses and prescriptions is often unavailable, even though such information is useful in defining circumstances that aid in confounding control and thereby causal inference.
We illustrate the utility of provider-level detail by drawing on our 2017 study, where a tenth of adults with depression initiating antidepressant therapy contemporaneously initiated benzodiazepine therapy. 2 While benzodiazepines have a limited role in treating depression, 3 contemporaneous benzodiazepine and antidepressant initiation in adults with depression potentially offers narrow shortterm benefits over antidepressant monotherapy. 4 In our study, we did not have information on prescriber, which left unresolved questions about whether the provider who diagnosed depression was also the antidepressant prescriber, and by extension, whether patients initiated an antidepressant for depression (or for another indication, such as anxiety, insomnia, and pain). 5 Further, for patients simultaneously initiating antidepressants and benzodiazepines, we were unable to determine whether simultaneous initiation was purposefully prescribed by one physician, or instead, whether the benzodiazepine was prescribed by a different provider (who may be unaware of the antidepressant prescription). Knowing the latter, for example, would allow us to examine whether untoward outcomes differ depending on whether simultaneous initiation is attributable to one or to more than one prescriber. We use provider details on patient diagnoses and dispensed prescriptions to estimate how often (a) adults were diagnosed with depression and prescribed an antidepressant by the same provider (eg, overall and by specialty, such as primary care physician vs. psychiatrist), and (b) simultaneous new users of antidepressants and benzodiazepines received prescriptions for both drugs by the same provider.
| METHODS
We used the IMS Health's LifeLink Health Plan Claims Database Simultaneous new benzodiazepine use was defined as a benzodiazepine dispensed on the same date as antidepressant initiation.
Provider variables included provider specialty from patient-level claims and a provider identification number, defined as the provider who directed services within a cluster. 8 Selected services were grouped into cluster providers (ie, provider directing set of services), and patients missing specialty provider information may include situations when no cluster provider was determined. 8 We selected 
KEY POINTS
• Provider details can inform observational research but are sometimes absent from claims databases; when prescriber details are unavailable, substituting the diagnosing provider to be the assumed prescriber may be warranted.
• In a large claims database with provider-level details on patient diagnoses and prescriptions, the vast majority of patients with depression diagnoses and antidepressant prescriptions received both from the same provider, as did the great majority of patients simultaneously initiating antidepressants and benzodiazepines.
• Whether these observations of high provider concordance generalize to other medications with multiple indications, or across other data sources, is unclear.
diagnosed with depression by a general practitioner received their antidepressant prescription from a general practitioner 98% of the time (psychiatrist = 92%; Table 1 ). For the small proportion of adults with a depression diagnosis from a social worker or psychologist (3% and 5%, respectively), we observed lower concordance: social work = 67% and psychologists = 74%. Ninety-three percent had provider identifier concordance between the depression diagnosis and antidepressant prescription (Table 1) .
When the depression diagnosis was the same day as antidepressant initiation (58% of initiators), the antidepressant prescriber was more likely to have diagnosed the depression (provider identifier concordance = 97%). For cases with 1 to 7 days between depression diagnosis and antidepressant prescription (25% of initiators), 89%
had concordant provider identifiers; 86% concordance in patients with more than 7 to 30 days between their diagnosis and prescription.
| Antidepressant vs. benzodiazepine prescriptions
Eight percent(n = 19 371) of antidepressant initiators simultaneously initiated a benzodiazepine. In simultaneous new users with known provider information, 94% had the same provider specialty on the antidepressant and benzodiazepine prescription, and 93% the same provider identifier (Table 1) Percentage concordant calculated among patients with nonmissing provider details; Missing depression diagnosis provider specialty: n = 12 122 (5%), missing antidepressant prescription provider specialty: n = 30 329 (12%); In simultaneous new users, missing antidepressant prescription provider specilaty: n = 2 243 (12%), missing benzodiazepine prescription provider specialty: n = 4 575 (24%).
d Counts/percentages exclude patients with missing provider specialty; Some provider specialty categories were nonspecific, the most common included: hospital = 0.8%; other facility = 0.7%; mental health/substance abuse facility = 0.3%
e Provider specialists with noteworthy prescribing restrictions; we cannot know whether or when these providers worked with a prescribing provider to coordinate care.
whether dissonance in provider status leads to higher rates of adverse outcomes.
| Research implications
In comparative effectiveness research, identifying a more restricted study cohort can reduce confounding by indication and keep research focused on a clinically relevant sample. 
| Considerations
Our data do not distinguish between provider facility (eg, multigroup practice) and individual providers. Given growth in integrated care networks, it is likely our data set ending in 2010 provides a better proxy for individual provider than more recent data. Actual provider concordance may vary over time, and we do not know how often patient care was coordinated between providers, including whether providers had the ability (or time) to view each other's diagnoses and prescriptions. We are uncertain whether an individual provider has consistent identifiers across facilities, in which case a concordant provider could appear nonconcordant. We can only evaluate provider concordance in cases with a recorded depression diagnosis. Given the low probability that an antidepressant prescription for depression has a depression diagnostic code in other datasources, 15 there are likely many adults initiating an antidepressant for depression but with no recorded diagnosis.
Some provider specialty variables are nonspecific (ie, hospital and urgent care); it is unclear how physicians with multiple specialties are classified. Lower provider concordance among psychologists and social workers is assumed to be a consequence of prescribing restrictions; we do not know whether prescriptions from provider specialties with limited prescribing privileges actually prescribed the medication or coordinated care with another prescribing provider. Results are limited to patients with nonmissing provider information. Even with provider details, when providers document multiple relevant diagnoses (ex, depression and anxiety), we cannot determine if the provider prescribed the medication to treat one indication or both concurrently.
| Conclusions
The vast majority of patients who received depression diagnoses and antidepressant prescriptions received both from the same provider.
The great majority of patients simultaneously initiating antidepressants and benzodiazepines appear to do so under the direction of a single provider. For these diagnoses and medications, when prescriber details are unavailable, substituting diagnosing provider for the assumed prescriber may be warranted within a small margin of error.
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